William Deraedt

8.9k total citations · 2 hit papers
56 papers, 2.7k citations indexed

About

William Deraedt is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, William Deraedt has authored 56 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Hematology, 25 papers in Oncology and 23 papers in Molecular Biology. Recurrent topics in William Deraedt's work include Multiple Myeloma Research and Treatments (47 papers), Protein Degradation and Inhibitors (19 papers) and Chronic Lymphocytic Leukemia Research (10 papers). William Deraedt is often cited by papers focused on Multiple Myeloma Research and Treatments (47 papers), Protein Degradation and Inhibitors (19 papers) and Chronic Lymphocytic Leukemia Research (10 papers). William Deraedt collaborates with scholars based in United States, Belgium and Germany. William Deraedt's co-authors include Antonio Palumbo, María‐Victoria Mateos, Helgi van de Velde, Andrew Cakana, Jordan M. Schecter, Ivan Špıčka, Tamás Masszi, Ming Qi, Ajay K. Nooka and Xiang Qin and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

William Deraedt

52 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

2016 1.1k citations Antonio Palumbo, Asher Chanan‐Khan et al. New England Journal of Medicine profile →
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

2011 661 citations Philippe Moreau, Halyna Pylypenko et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
William Deraedt United States	15	2.2k	1.7k	1.5k	410	225	56	2.7k
Ivan Špıčka Czechia	24	3.1k 1.4×	2.4k 1.4×	2.1k 1.4×	474 1.2×	249 1.1×	141	3.7k
Lotfi Benboubker France	26	3.0k 1.3×	2.7k 1.5×	2.0k 1.3×	571 1.4×	258 1.1×	101	3.7k
Jean‐Luc Harousseau France	20	2.6k 1.2×	2.2k 1.3×	1.6k 1.1×	425 1.0×	218 1.0×	45	3.4k
Antonio Palumbo Italy	34	3.5k 1.5×	2.6k 1.5×	2.0k 1.3×	485 1.2×	286 1.3×	131	4.0k
Martin Kropff Germany	26	2.5k 1.1×	2.1k 1.2×	1.7k 1.1×	368 0.9×	155 0.7×	69	3.1k
Hang Quach Australia	23	1.8k 0.8×	1.4k 0.8×	1.4k 0.9×	343 0.8×	534 2.4×	209	2.6k
María Teresa Cibeira Spain	23	1.3k 0.6×	1.3k 0.8×	709 0.5×	398 1.0×	182 0.8×	91	2.0k
Rakesh Popat United Kingdom	29	1.9k 0.9×	1.7k 1.0×	1.4k 0.9×	282 0.7×	199 0.9×	154	2.7k
Hareth Nahi Sweden	30	2.0k 0.9×	1.6k 0.9×	1.5k 1.0×	437 1.1×	559 2.5×	143	3.0k
Darrell White Canada	23	1.3k 0.6×	998 0.6×	1.0k 0.6×	311 0.8×	263 1.2×	134	1.9k

Countries citing papers authored by William Deraedt

Since Specialization

Citations

This map shows the geographic impact of William Deraedt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Deraedt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Deraedt more than expected).

Fields of papers citing papers by William Deraedt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Deraedt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Deraedt. The network helps show where William Deraedt may publish in the future.

Co-authorship network of co-authors of William Deraedt

This figure shows the co-authorship network connecting the top 25 collaborators of William Deraedt. A scholar is included among the top collaborators of William Deraedt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Deraedt. William Deraedt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dhakal, Binod, Hermann Einsele, Jordan M. Schecter, et al.. (2024). Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron database. Blood Advances. 8(19). 5062–5071. 3 indexed citations

Cohen, Adam D., Mounzer Agha, Jesús F. San Miguel, et al.. (2024). PCR134 Psychometric Properties of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Analysis of Phase 2 CARTITUDE-2 Study Cohorts A, B, and C. Value in Health. 27(6). S320–S320.

Delforge, Michel, María‐Victoria Mateos, Kristina Carlson, et al.. (2024). Efficacy of Carvykti in Cartitude-4 Versus Alternative Treatments from Daratumumab Clinical Trials for the Treatment of Patients with Lenalidomide-Refractory Multiple Myeloma. Blood. 144(Supplement 1). 7085–7085. 3 indexed citations

Yong, Kwee, Hermann Einsele, Jordan M. Schecter, et al.. (2024). Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials. European Journal of Cancer. 215. 115157–115157. 2 indexed citations

Crawford, Rebecca, Katharine S. Gries, Satish Valluri, et al.. (2022). The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapies. Cancer Reports. 5(11). e1603–e1603. 7 indexed citations

Weisel, Katja, Amrita Krishnan, Jordan M. Schecter, et al.. (2022). Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 22(9). 690–701. 10 indexed citations

Einsele, Hermann, Niels W.C.J. van de Donk, Bertrand Arnulf, et al.. (2021). CARTITUDE-2: Phase 2 Multicohort Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma. Transplantation and Cellular Therapy. 27(3). S433–S434.

Martin, Tom, Saad Z. Usmani, Jordan M. Schecter, et al.. (2021). Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Current Medical Research and Opinion. 37(10). 1779–1788. 34 indexed citations

Dytfeld, Dominik, Binod Dhakal, Mounzer Agha, et al.. (2021). Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5). Blood. 138(Supplement 1). 1835–1835. 26 indexed citations

10.

Jakubowiak, Andrzej, Saad Z. Usmani, Amrita Krishnan, et al.. (2021). Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 21(10). 701–710. 10 indexed citations

11.

Xu, Xu Steven, Philippe Moreau, Saad Z. Usmani, et al.. (2020). Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. Advances in Therapy. 37(4). 1464–1478. 9 indexed citations

12.

Cavo, Michèle, Meletios Α. Dimopoulos, Jesús F. San Miguel, et al.. (2020). Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies. Clinical Lymphoma Myeloma & Leukemia. 20(7). 480–489. 6 indexed citations

13.

Palumbo, Antonio, Asher Chanan‐Khan, Katja Weisel, et al.. (2016). Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine. 375(8). 754–766. 1056 indexed citations breakdown →

14.

Weisel, Katja, Antonio Palumbo, Asher Chanan‐Khan, et al.. (2016). Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR. Annals of Oncology. 27. vi313–vi313. 1 indexed citations

15.

Moreau, Philippe, Vadim Doronin, Alexander Schmidt, et al.. (2012). Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma. Clinical Pharmacokinetics. 51(12). 823–829. 68 indexed citations

16.

Moreau, Philippe, Halyna Pylypenko, Sebastian Grosicki, et al.. (2011). Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. The Lancet Oncology. 12(5). 431–440. 661 indexed citations breakdown →

17.

Dimopoulos, Meletios Α., María-Victoria Mateos, Paul G. Richardson, et al.. (2010). Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. European Journal Of Haematology. 86(1). 23–31. 100 indexed citations

18.

Schlag, Rudolf, Meletios Α. Dimopoulos, Ofer Shpilberg, et al.. (2009). A246 VMP Results in Fewer Bone Events and Greater ALP Increases Versus MP in the VISTA Study in Front-Line MM. Clinical Lymphoma & Myeloma. 9. S43–S43. 2 indexed citations

19.

Palumbo, Antonio, Rudolf Schlag, Nuriet K. Khuageva, et al.. (2008). Prolonged therapy with bortezomib plus melphalan-prednisone (vmp) results in improved quality and duration of response in the phase iii vista study in previously untreated multiple myeloma (mm). 93. 83–83. 7 indexed citations

20.

Chen, George, et al.. (2007). Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica. 92(10). 1399–1406. 199 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact